[ad_1]
BEIJING (Reuters) – The US pharmaceutical group Beogen and its Japanese partner Essay have decided to end two late-stage clinical trials of adocanumab, a drug for the treatment of Alzheimer's disease. is a major setback for the search for a cure for the disease that struck a baby and had lost more than 18 billion dollars.
The experts considered the drug as one of the latest experiments on the assumption that removing amyloid sediment from the patient's brain during the early stages of the disease could put an end to the deterioration of the condition, which includes memory loss and personal care.
Peugeot shares fell by nearly 30% after the decision and posted a drop of 225.70 USD, the largest decline since February 2005.
The decision to discontinue the tests came after an independent monitoring body stated that there was more hope in the success of the tests based on the ## 147 ## # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # 39, analysis of property data.
In July, Essay announced promising results for another Alzheimer's disease drug, PEN-2401, which he is developing with Beogen. The drug failed in a 12-month analysis.
Any effective treatment for Alzheimer's disease, which affects approximately 5.7 million Americans, will surely become one of the best-selling drugs in the world. But efforts to date have not paid off, with more than 100 experimental drugs failing.
Clinical trials were in the late stages of the adocanumab test in patients with mild cognitive impairment or mild dementia. The detailed results will be presented at an upcoming medical meeting.
"This disappointing news underscores the extremely difficult treatment of Alzheimer's disease and the need to further enhance the neuroscience," said Michael Fontaines, CEO of Peugeot.
Biogen and Isai said they would continue to work on other treatments for the disease, including PEN 2401.
[ad_2]
Source link
